LINC01607 promotes hepatocellular carcinoma progression and ferroptosis-associated therapy resistance with functional involvement of the p62–Keap1–Nrf2 pathway
Cancer Drug Resistance · 17.07.2026
DOI: 10.20517/cdr.2026.02 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Drug Resistance, online erschienen am 17.07.2026. Verfasst von Yuxin Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Hepatocellular carcinoma (HCC) remains a formidable worldwide health challenge, characterized by inadequate treatment efficacy and unsatisfactory clinical prognosis. Our previous study implicated LINC01607 in lenvatinib resistance, but its role in HCC progression and ferroptosis-associated vulnerability remains unclear.
Methods
LINC01607 expression was examined in HCC patient samples and The Cancer Genome Atlas datasets. Cellular, animal, and patient-derived organoid (PDO) models were used to evaluate its biological function. RNA sequencing, ferroptosis-related assays, rescue experiments, and drug-sensitivity analyses were performed to explore associated downstream pathways.
Results
LINC01607 was upregulated in HCC tissues and associated with aggressive clinicopathological features and poor survival. Functional assays showed that LINC01607 promoted HCC cell proliferation, migration, invasion, tumor growth, and metastasis. LINC01607 depletion induced ferroptosis-associated changes, including increased lipid peroxidation, glutathione depletion, and Fe2+ accumulation under ferroptotic stress, which were partially reversed by ferroptosis inhibitors. LINC01607 knockdown also enhanced sensitivity to RSL3 and sorafenib, while ferrostatin-1 partially rescued the increased sorafenib sensitivity. RNA sequencing and rescue experiments suggested involvement of the p62–Keap1–Nrf2 pathway. LINC01607 depletion was associated with reduced SQSTM1/p62, Nrf2, and ferroptosis-resistance proteins, whereas p62 overexpression partially reversed these effects and Nrf2 knockdown abrogated the rescue. In xenograft and PDO models, LINC01607 depletion improved the response to sorafenib.
Conclusion
LINC01607 contributes to HCC progression and ferroptosis-associated therapy resistance, at least in part through the p62–Keap1–Nrf2 pathway, supporting further investigation of LINC01607 as a potential therapeutic target.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China.
- Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, Chin…
- Authors contributed equally to this work.
- Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi, China.
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China.
- Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, College of Medicine, Shihezi University, Shihezi 832008, Xinjiang, China.
Zitieren
APA
Zhang, Y., Xu, W., Cheng, F., Zhu, J., Lu, Y., Cai, G., Li, J., & Zhang, Y. (2026). LINC01607 promotes hepatocellular carcinoma progression and ferroptosis-associated therapy resistance with functional involvement of the p62–Keap1–Nrf2 pathway. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2026.02
Vancouver
Zhang Y, Xu W, Cheng F, Zhu J, Lu Y, Cai G, et al. LINC01607 promotes hepatocellular carcinoma progression and ferroptosis-associated therapy resistance with functional involvement of the p62–Keap1–Nrf2 pathway. Cancer Drug Resistance. 2026. doi:10.20517/cdr.2026.02
BibTeX
@article{Zhang2026,
author = {Zhang, Yuxin and Xu, Weiqi and Cheng, Fangling and Zhu, Jinghan and Lu, Yuanxiang and Cai, Guangzhen and Li, Jiang and Zhang, Yujie},
title = {LINC01607 promotes hepatocellular carcinoma progression and ferroptosis-associated therapy resistance with functional involvement of the p62–Keap1–Nrf2 pathway},
journal = {Cancer Drug Resistance},
year = {2026},
doi = {10.20517/cdr.2026.02}
}
EUVIMED